The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The genomic landscape of IgM MGUS & stable vs progressive asymptomatic WM
Tina Bagratuni, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses a study focusing on the genomic landscape of IgM monoclonal gammopathy of undetermined significance (MGUS) and asymptomatic Waldenström’s macroglobulinemia (WM). The study analyzed both stable and progressive asymptomatic patients, identifying specific genomic features, such as higher mutation burdens and CNV events, in those who progressed to symptomatic disease. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
